YFLJH GlobalChina Peptide API Partner

2026-06-23

Core Advantages of China Peptide CDMO Support for Overseas B2B Clients

This article analyzes the core advantages of Chinese peptide CDMOs in supporting overseas B2B pharmaceutical clients, focusing on quality documentation, regulatory communication, supplier qualification, and supply chain collaboration.

✓For qualified B2B partners only. Documentation available upon request. Not for personal use or direct consumer sale.

Source references

  1. ICH Q3A(R2) Impurities in New Drug Substances

    International Council for Harmonisation

    Guidance on impurity profiling and qualification

  2. FDA Guidance for Industry: Drug Master Files

    U.S. Food and Drug Administration

    Regulatory dossier expectations and DMF usage

  3. EDQM CEPs and Quality Standards

    European Directorate for the Quality of Medicines & HealthCare

    Pharmacopeial compliance and CEP documentation